2012-08-24T13:34:57-04:00 2011-12-31 ARGY WILTSE & ROBINSON PC 8405 GREENSBORO DRIVE 7TH FLOOR MCLEAN VA 22102 990 2011-01-01 912059167 CYSTIC FIBROSIS FOUNDATION THERAPEUTICS INC % ROBERT J BEALL PHD CYST 3019514422 6931 ARLINGTON ROAD BETHESDA MD 20814 ROBERT J BEALL PHD 2012-08-23 true DAVID J TRIMNER 7038930600 2011 2016-02-24 21:20:13Z ROBERT J BEALL PHD 6931 ARLINGTON ROAD STE 200 BETHESDA MD 20814 100420758 false X www.CFF.ORG/RESEARCH/CFFT/ X 2000 MD The mission is to assure the development of the means to cure and control cystic fibrosis (cf) and to improve the quality of life for those with the disease. 7 6 12 0 0 0 0 99865046 400446 551511 369 188 53761115 4013 54161930 100420758 29412613 27991951 0 0 2842375 3008405 0 0 0 21906942 19487879 54161930 50488235 49932523 67639625 28133165 67639625 28133165 0 0 THE MISSION IS TO ASSURE THE DEVELOPMENT OF THE MEANS TO CURE AND CONTROL CYSTIC FIBROSIS (CF) AND TO IMPROVE THE QUALITY OF LIFE FOR THOSE WITH THE DISEASE. A LIFE SHORTENING GENETIC DISEASE, CF AFFECTS THE LUNGS AND DIGESTIVE SYSTEMS OF NEARLY 30,000 CHILDREN AND YOUNG ADULTS IN THE U.S. CURRENTLY, THERE IS NO CURE. false false 20415616 0 0 INVESTMENTS BY CYSTIC FIBROSIS FOUNDATION THERAPEUTICS (CFFT) IN STATE-OF-THE-ART RESEARCH HAVE ACCELERATED PROGRESS TOWARD DEVELOPING NEW CF TREATMENTS AND FINDING A CURE FOR THE DISEASE. BY INVESTING IN CF DRUG DISCOVERY AND DEVELOPMENT RESEARCH CONDUCTED BY BIOTECHNOLOGY COMPANIES AND PROVIDING MATCHING AWARDS TO CF DRUG DEVELOPERS FOR CF RESEARCH, AND WITH A SPECIALIZED CF CLINICAL TRIALS NETWORK, CFFT HAS ATTRACTED SIGNIFICANT INDUSTRY INVOLVEMENT IN THE FIGHT AGAINST CF. IN 2011, PHASE 3 CLINICAL TRIALS OF VX-770 SHOWED PROFOUND RESULTS. THOSE RECEIVING THE DRUG DEMONSTRATED THE HIGHEST INCREASE ON A LUNG FUNCTION TEST SEEN IN ANY CLINICAL TRIAL OF A CF DRUG. A NEW DRUG APPLICATION TO THE FDA FOR VX-770 UNDER THE TRADE NAME KALYDECO WAS SUBMITTED BY VERTEX PHARMACEUTICALS. RESULTS FROM THE FIRST PART OF AN ONGOING PHASE 2 TRIAL TESTING KALYDECO IN COMBINATION WITH VX-809 SHOW PROMISING RESULTS IN PEOPLE WITH THE MOST COMMON CF MUTATION, DELTA F508. CFFT HAS A UNIQUE AND SUCCESSFUL APPROACH TO SEEKING THE DEVELOPMENT OF DRUGS FOR A RARE DISEASE. THIS DRUG DEVELOPMENT MODEL HAS HELPED CREATE A PIPELINE THAT AT THE END OF 2011 HAD NEARLY 30 PROMISING DRUGS TO FIGHT CYSTIC FIBROSIS. 29724286 27991951 551511 Medical Programs in 2011 consisted of costs to support scientific study and investigations. 144 grants were awarded in 2011. 0 0 0 50139902 true true false false false false false false false true false false true false false false true false false true true false false false false false true false true false false false false false false false false false false false false false true false false false false true 70 0 12 true false false false false false false false false false false X 7 6 false false false false false true false true true false false true true true true true true true true false X X ROBERT J BEALL PHD 3019514422 6931 ARLINGTON ROAD STE 200 BETHESDA MD 20814 X Theodore J Torphy PhD 5.0 X 0 0 0 STEVEN SHAK MD 3.0 X 0 0 0 CATHERINE C MCLOUD 3.0 X 0 0 0 JONATHAN COHN MD 3.0 X 0 0 0 JASON M ARYEH 3.0 X 0 0 0 D PAUL FLESSNER 3.0 X 0 0 0 Robert J Beall PhD 18.0 X X 234488 477065 362172 Preston W Campbell MD 18.0 X 156360 310778 268893 C Richard Mattingly 5.0 X 0 475320 284459 Vera H Twigg 5.0 X 0 325228 119955 BRUCE MARSHALL MD 50.0 X 339453 0 26029 CYNTHIA GEORGE MSN FNP BC 50.0 X 111524 0 15333 MARTIN MENSE 50.0 X 161275 0 43814 ELIZABETH JOSELOFF PHD 50.0 X 103125 0 27904 1106225 1588391 1148559 6 false true false VERTEX PHARMACEUTICALS LLC 130 WAVERLY STREET CAMBRIDGE MA 02139 CONTRACTED RESEARCH 9222356 CHANTEST INC 14556 NEO PARKWAY CLEVELAND OH 44128 RESEARCH SUPPORT 2275000 PFIZER INC 100 ACORN PARK DRIVE CAMBRIDGE MA 02140 CONTRACTED RESEARCH 3125718 OUTCOME SCIENCES INC PO BOX 983022 BOSTON MA 022983022 CLINICAL RESEARCH 433655 SCHANER LUBITZ PLLC 6931 ARLINGTON ROAD SUITE 200 BETHESDA MD 20814 LEGAL SERVICES 261943 5 49932523 49932523 99865046 CLINICAL STUDY 541900 222000 222000 REFUNDED OR CANCELLED GRANTS 900099 329511 329511 551511 188 188 0 4013 4013 0 0 0 0 0 100420758 551511 4201 26106741 26106741 3399 3399 1881811 1881811 0 390848 355302 35546 0 0 2150172 1954623 195549 0 112997 102720 10277 0 210588 191436 19152 0 143800 129760 14040 0 0 0 0 0 261943 261943 0 0 4790 0 4790 0 0 0 0 3705 0 3705 0 0 180560 163062 17498 0 319734 303417 16317 0 0 204557 183530 21027 0 78786 74058 4728 0 0 57270 56020 1250 0 0 0 63346 60621 2725 0 141709 141709 0 0 CONTRACTED RESEARCH 17916553 17916553 0 0 CHEMISTRY 252000 252000 0 0 MISCELLANEOUS 2926 1197 1729 50488235 50139902 348333 0 0 0 1068631 3733071 0 0 66488635 2249263 0 0 0 0 0 0 0 0 32500 229498 445281 287872 49859 157409 0 0 0 0 0 0 0 0 0 21763924 67639625 28133165 16758245 989715 22749014 27143450 0 0 0 0 0 0 0 0 0 0 0 0 28132366 0 67639625 28133165 X 0 0 0 0 0 0 0 0 67639625 28133165 X 49932523 -49932523 X false true true X false X X X false false false CYSTIC FIBROSIS FOUNDATION 131930701 03 true true true 0 1 0 RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 445281 287872 157409 157409 INTERCOMPANY RECEIVABLE 21763924 21763924 true North America Grantmaking NONE 744001 Europe (Including Iceland and Greenland) Grantmaking NONE 1004812 East Asia and the Pacific Grantmaking NONE 50000 Middle East and North Africa Grantmaking NONE 82998 1881811 1881811 North America CLINICAL RESEARCH 166571 CHECK North America DRUG DISCOVERY 216000 CHECK North America DRUG DISCOVERY 262660 CHECK North America DRUG DISCOVERY 98770 CHECK Europe/Iceland/Greenland CLINICAL RESEARCH 58000 WIRE Europe/Iceland/Greenland CLINICAL RESEARCH 230585 WIRE Europe/Iceland/Greenland CLINICAL RESEARCH 18051 WIRE Europe/Iceland/Greenland DRUG DISCOVERY 151297 WIRE Europe/Iceland/Greenland DRUG DISCOVERY 277952 WIRE Europe/Iceland/Greenland DRUG DISCOVERY 168927 CHECK Europe/Iceland/Greenland DRUG DISCOVERY 100000 WIRE East Asia/Pacific CLINICAL RESEARCH 50000 WIRE Middle East/North Africa DRUG DISCOVERY 82998 WIRE 12 false false false false false false Procedures for monitoring grant funds outside of the U.S. Schedule F, Part I, Line 2 THE ORGANIZATION HAS PROCEDURES IN PLACE TO MONITOR THE SCIENTIFIC PROGRESS AND FINANCIAL ASPECTS OF GRANTS AWARDED TO ENTITIES OUTSIDE OF THE UNITED STATES. THE ORGANIZATION FOLLOWS THE U.S. DEPARTMENT OF TREASURY ANTI-TERRORIST FINANCING VOLUNTARY BEST PRACTICES GUIDELINES FOR CHARITIES. IN COMPLIANCE WITH THE BEST PRACTICES, THE ORGANIZATION COLLECTS AND REVIEWS INFORMATION ABOUT THE PROSPECTIVE GRANTEES AND CONDUCTS A VETTING PROCESS TO ENSURE THEY ARE NOT SUSPECTED OF ACTIVITIES RELATED TO TERRORISM. ONCE A GRANT IS APPROVED, A WRITTEN AGREEMENT IS SIGNED BY BOTH THE ORGANIZATION AND THE GRANTEE. FUNDING IS INCREMENTAL AND SPONSORED INSTITUTIONS ARE REQUIRED TO SUBMIT ANNUAL REPORTS OF EXPENDITURES AS WELL AS SCIENTIFIC PROGRESS REPORTS. SCIENTIFIC REPORTS ARE REVIEWED BY THE ORGANIZATION'S SCIENTIFIC STAFF TO DETERMINE PROGRESS. THE FINAL GRANT PAYMENT IS CONTINGENT UPON RECEIPT AND APPROVAL OF THE REPORT OF EXPENDITURES. REPORTS OF EXPENDITURES ARE REVIEWED AND APPROVED BY STAFF TO ENSURE INCURRED COSTS ARE APPROPRIATE. THE CF FOUNDATION'S INTERNAL AUDITORS CONDUCT AUDITS ON SAMPLES OF GRANT EXPENDITURE REPORTS BY EXAMINING SUPPORTING RECORDS FROM THE SPONSORED INSTITUTIONS. THE GRANT IN THE MIDDLE EAST/NORTH AFRICA REGION WAS MADE TO A UNIVERSITY IN ISRAEL. true Albany Medical College 47 New Scotland Ave Mail Code 88 Albany NY 12208 141338310 501c(3) 74088 CLINICAL RESEARCH STUDY All Children's Hospital Dept 9010 PO Box 31020 St Petersburg FL 33731 590683252 501c(3) 80438 CLINICAL RESEARCH STUDY Arizona Board of Regents University of Arizona Sponsored Projects Services 888 N Euclid Room 510 Tucson AZ 85722 742652689 501c(3) 134938 CLINICAL RESEARCH AWARDS Arizona Board of Regents University of Arizona Sponsored Projects Services 888 N Euclid Room 510 Tucson AZ 85722 742652689 501c(3) 71217 CLINICAL RESEARCH STUDY Baylor College of Medicine PO Box 1 Houston TX 77212 741613878 501c(3) 98537 CLINICAL RESEARCH STUDY Beth Israel Medical Center Office of Grants Contracts New York NY 10038 135564934 501c(3) 74088 CLINICAL RESEARCH STUDY Case Western Reserve University 10900 Euclid Avenue 160 Water Street 24th Floor Cleveland OH 441067015 341018992 501c(3) 261084 CLINICAL RESEARCH STUDY Case Western Reserve University 10900 Euclid Avenue Cleveland OH 441067015 341018992 501c(3) 169525 PHASE III TRIALS Case Western Reserve University 10900 Euclid Avenue Suite 208 Cleveland OH 441067015 341018992 501c(3) 137362 CLINICAL RESEARCH AWARDS Children's & Women's Physicians of Westchester LL Pediatrics Department Munger Pavilion Room 123 Valhalla NY 10595 133940462 501c(3) 68976 CLINICAL RESEARCH STUDY Children's Health Care 2525 Chicago Avenue South Munger Pavilion Room 123 Minneapolis MN 554041844 411754276 501c(3) 63504 CLINICAL RESEARCH STUDY Children's Hospital Corporation 300 Longwood Avenue Boston MA 02115 042774441 501c(3) 98537 CLINICAL RESEARCH STUDY Children's Hospital Corporation 300 Longwood Avenue Boston MA 02115 042774441 501c(3) 68250 CLINICAL RESEARCH AWARDS Children's Hospital Medical Center of Akron 1 Perkins Square Akron OH 44308 340714357 501c(3) 80438 CLINICAL RESEARCH STUDY Children's Hospital Medical Center Cincinnati 3333 Burnet Avenue Cincinnati OH 45229 310833936 501c(3) 260406 CLINICAL RESEARCH STUDY Children's Hospital Medical Center Cincinnati 3333 Burnet Avenue Cincinnati OH 45229 310833936 501c(3) 135386 CLINICAL RESEARCH AWARDS Children's Hospital Medical Center Cincinnati 3333 Burnet Avenue Cincinnati OH 45229 310833936 501c(3) 25612 ACADEMIC ADVISORY AWARDS Children's Medical Center One Childrens Plaza Dayton OH 45404 310672132 501c(3) 68976 CLINICAL RESEARCH STUDY Children's Memorial Hospital 2300 Childrens Plaza Chicago IL 60614 363357006 501c(3) 172800 CLINICAL RESEARCH STUDY Connecticut Children's Medical Center 282 Washington Street Box 43 Hartford CT 06106 060646755 501c(3) 78830 CLINICAL RESEARCH STUDY Cook Children's Medical Center 801 Seventh Avenue Ft Worth TX 76104 752051646 501c(3) 66864 CLINICAL RESEARCH STUDY Drexel University College of Medicine Erie Ave at Front St Philadelphia PA 191291192 232979433 501c(3) 76416 CLINICAL RESEARCH STUDY Duke University Medical Center Box 3001 Suite 2215 Durham NC 27710 560532129 501c(3) 59736 CLINICAL RESEARCH STUDY Emory University 1784 N Decatur Road Atlanta GA 30322 580566256 501c(3) 298646 CLINICAL RESEARCH AWARDS Emory University 1784 N Decatur Road Suite 510 Atlanta GA 30322 580566256 501c(3) 93887 CLINICAL RESEARCH STUDY Kaiser Foundation Research Institute 1800 Harrison Street Suite 510 Oakland CA 94612 941105628 501c(3) 59122 CLINICAL RESEARCH STUDY Maine Medical Center 22 Bramhall Street 16th Floor Portland ME 041023175 010238552 501c(3) 227276 CLINICAL RESEARCH AWARDS Maine Medical Center 22 Bramhall Street Portland ME 041023175 010238552 501c(3) 66206 CLINICAL RESEARCH STUDY Medical University of South Carolina PO Box 997 Charleston SC 29402 576000722 501c(3) 84672 CLINICAL RESEARCH STUDY Monmouth Medical Center Foundation 300 Second Avenue Long Branch NJ 07740 222456079 501c(3) 74088 CLINICAL RESEARCH STUDY National Jewish Medical and Research Center 1400 Jackson Street Denver CO 80206 742044647 501c(3) 123374 CLINICAL RESEARCH AWARDS Nemours Children's Clinic - Jacksonville 807 Nira Street Jacksonville FL 32207 590634433 501c(3) 174554 CLINICAL RESEARCH STUDY Oregon Health & Science University Sponsored Projects Administration O Portland OR 97239 237083114 501c(3) 270000 DRUG DISCOVERY AWARDS Oregon Health & Sciences University 3181 SW Sam Jackson Park Road 0690 SW Bancroft Street Portland OR 97201 237083114 501c(3) 80438 CLINICAL RESEARCH STUDY Pennsylvania State University College of Medicine L-106 Hershey PA 17033 246000376 501c(3) 80438 CLINICAL RESEARCH STUDY Phoenix Children's Hospital 1300 North 12th Street Office of Research Affairs H138 Phoenix AZ 85006 860422559 501c(3) 68976 CLINICAL RESEARCH STUDY Providence Alaska Medical Center 4045 Lake Otis Pkwy 209 Anchorage AK 99508 920016429 501c(3) 63504 CLINICAL RESEARCH STUDY Regents of the University of Colorado Grants Contracts 13123 East 16th Avenue B395 Aurora CO 800450508 846000555 501c(3) 9767 ACADEMIC ADVISORY AWARDS Regents of the University of Colorado at Denver Grants and Contracts Mail Stop F42 F428 Fitzsimons Building 500 Aurora CO 80045 846000555 501c(3) 61358 PHASE III TRIALS Regents of the University of Colorado at Denver Grants and Contracts Mail Stop F42 Anschutz Medical Campus Bldg 500 Aurora CO 80045 846000555 501c(3) 26839 CLINICAL RESEARCH AWARDS Regents of the University of Colorado at Denver an The Childrens Hospital Anschutz Medical Campus Bldg 500 Aurora CO 80045 846000555 501c(3) 146088 CLINICAL RESEARCH STUDY Research Foundation of SUNY on behalf of Univ at 402 Crofts Hall 13123 East 16th Avenue B395 Buffalo NY 142607016 141368361 501c(3) 28728 CLINICAL RESEARCH AWARDS Research Foundation of SUNY on behalf of Upstate M PO Box 9 University at Buffalo Albany NY 122010009 141368361 501c(3) 84625 CLINICAL RESEARCH STUDY Rosalind Franklin University of Medicine and Scien Green Bay Road North Chicago IL 60064 362181973 501c(3) 808261 DRUG DISCOVERY AWARDS Sanford Childrens Specialty Clinic 1305 W 18th Street Sioux Falls SD 57117 460447693 501c(3) 60329 CLINICAL RESEARCH STUDY Seattle Children's Hospital 4800 Sand Point Way NE Seattle WA 98105 910564748 501c(3) 4093054 CLINICAL RESEARCH STUDY Seattle Children's Hospital 4800 Sand Point Way NE Seattle WA 98105 910564748 501c(3) 3133321 PHASE III TRIALS Seattle Children's Hospital 4800 Sand Point Way NE Seattle WA 98105 910564748 501c(3) 463732 CLINICAL RESEARCH AWARDS Seton Healthcare 4900 Mueller Blvd Austin TX 78723 741109643 501c(3) 80438 CLINICAL RESEARCH STUDY Spectrum Health Downtown Campus DCMC Administration 3rd Floor Grand Rapids MI 49503 382752328 501c(3) 66864 CLINICAL RESEARCH STUDY St Louis University 3500 Lindell Blvd 100 Michigan Street NE St Louis MO 63103 430654872 501c(3) 70384 CLINICAL RESEARCH STUDY St Luke's Regional Medical Center 100 East Idaho Boise ID 83712 820161600 501c(3) 63504 CLINICAL RESEARCH STUDY Stanford University 651 Serra Street Suite 220 Suite 200 Stanford CA 943056215 941156365 501c(3) 171687 CLINICAL RESEARCH STUDY Stanford University 651 Serra Street Suite 220 Mail Code 5402 Stanford CA 943056215 941156365 501c(3) 167447 CLINICAL RESEARCH AWARDS Texas Tech University Health Sciences Center 3601 4th Street Stop 6540 Mail Code 5402 Lubbock TX 79430 752668014 501c(3) 151903 DRUG DISCOVERY AWARDS The Children's Hospital Association 13123 East 16th Avenue B321 MC0831 Aurora CO 80045 840166760 501c(3) 382825 CLINICAL RESEARCH AWARDS The Children's Hospital Association 13123 East 16th Avenue B321 Room 1044 Aurora CO 80045 840166760 501c(3) 172800 CLINICAL RESEARCH STUDY The Children's Hospital of Philadelphia 34th and Civic Center Boulevard Room 1044 Philadelphia PA 19104 231352166 501c(3) 94772 CLINICAL RESEARCH STUDY The Children's Mercy Hospital 2401 Gillham Road 200 Oak Street SE Suite 450 Kansas City MO 61408 440605373 501c(3) 80438 CLINICAL RESEARCH STUDY The Feinstein Institute for Medical Research 350 Community Drive Manhasset NY 11030 112673595 501c(3) 80438 CLINICAL RESEARCH STUDY The General Hospital Corporation (aka Massachuse PO Box 414876 Boston MA 022414876 042697983 501c(3) 85729 DRUG DISCOVERY AWARDS The General Hospital Corporation (aka Massachuse 55 Fruit Street General Post Office Boston MA 02114 042697983 501c(3) 80438 CLINICAL RESEARCH STUDY The Johns Hopkins University 600 N Wolfe Street Park 316 General Post Office Baltimore MD 21205 520595110 501c(3) 608417 CLINICAL RESEARCH AWARDS The Johns Hopkins University 600 N Wolfe Street Park 316 Baltimore MD 21205 520595110 501c(3) 361130 DRUG DISCOVERY AWARDS The Johns Hopkins University 600 N Wolfe Street Park 316 Baltimore MD 21205 520595110 501c(3) 197700 CLINICAL RESEARCH STUDY The Johns Hopkins University 600 N Wolfe Street Park 316 Suite 620 ACC Baltimore MD 21205 520595110 501c(3) 154910 PHASE III TRIALS The Johns Hopkins University 600 N Wolfe Street Park 316 Suite 620 ACC Baltimore MD 21205 520595110 501c(3) 24752 ACADEMIC ADVISORY AWARDS The Medical College of Wisconsin 8701 Watertown Plk Rd 970 E 58th Street Milwaukee WI 53226 390806261 501c(3) 75937 CLINICAL RESEARCH STUDY The Rector and Visitors of the University of Virgi Office of Sponsored Programs Charlottesville VA 229044195 546001796 501c(3) 84658 CLINICAL RESEARCH STUDY The Regents of the University of California San D 9500 Gilman Dr PO Box 400195 La Jolla CA 920930984 956006144 501c(3) 107787 DRUG DISCOVERY AWARDS The Regents of the University of California San D 9500 Gilman Dr MC0954 La Jolla CA 920930984 956006144 501c(3) 63079 CLINICAL RESEARCH STUDY The Regents of the University of California San D 9500 Gilman Dr MC0954 La Jolla CA 920930984 956006144 501c(3) 62681 CLINICAL RESEARCH AWARDS The Regents of The University of Michigan 3003 South State Street MC 0954 Ann Arbor MI 481091274 386006309 501c(3) 379907 CLINICAL RESEARCH AWARDS The Regents of The University of Michigan 3003 South State Street Room 1044 Ann Arbor MI 481091274 386006309 501c(3) 100548 CLINICAL RESEARCH STUDY The Regents of the University of Minnesota Sponsored Projects Administration Room 1044 Minneapolis MN 554552070 416007513 501c(3) 167922 CLINICAL RESEARCH STUDY The Regents of the University of Minnesota Sponsored Projects Administration 200 Oak Street SE Suite 450 Minneapolis MN 554552070 416007513 501c(3) 68250 CLINICAL RESEARCH AWARDS The Research Institute at Nationwide Children's Ho 700 Childrens Drive 200 Oak Street SE Suite 450 Columbus OH 43205 316056230 501c(3) 108754 CLINICAL RESEARCH STUDY The Research Institute at Nationwide Children's Ho 700 Childrens Drive Columbus OH 43205 316056230 501c(3) 37594 DRUG DISCOVERY AWARDS The Scripps Research Institute 10666 North Torrey Pines Road La Jolla CA 92037 330435954 501c(3) 504000 DRUG DISCOVERY AWARDS The Toledo Hospital 2142 N Cove Blvd Toledo OH 43606 344428256 501c(3) 84672 CLINICAL RESEARCH STUDY The Trustees of Columbia University in the City of PO Box 29789 New York NY 100879789 135598093 501c(3) 123240 DRUG DISCOVERY AWARDS The Trustees of Columbia University in the City of PO Box 29789 General Post Office New York NY 100879789 135598093 501c(3) 62855 CLINICAL RESEARCH STUDY The Trustees of Columbia University in the City of PO Box 29789 General Post Office New York NY 100879789 135598093 501c(3) 23906 ACADEMIC ADVISORY AWARDS The University of Alabama at Birmingham 1600 7th Avenue South General Post Office Birmingham AL 35233 636005396 501c(3) 1118746 DRUG DISCOVERY AWARDS The University of Alabama at Birmingham 1600 7th Avenue South Suite 620 ACC Birmingham AL 35233 636005396 501c(3) 408121 CLINICAL RESEARCH STUDY The University of Alabama at Birmingham 1600 7th Avenue South Suite 620 ACC Birmingham AL 35233 636005396 501c(3) 56851 ACADEMIC ADVISORY AWARDS The University of Alabama at Birmingham 1600 7th Avenue South Suite 620 ACC Birmingham AL 35233 636005396 501c(3) 23792 PHASE III TRIALS The University of Chicago University Research Administration Suite 620 ACC Chicago IL 60637 362177139 501c(3) 59122 CLINICAL RESEARCH STUDY The University of Chicago University Research Administration 970 E 58th Street Chicago IL 60637 362177139 501c(3) 30366 ACADEMIC ADVISORY AWARDS The University of Iowa Office of Vice President for Resear 970 E 58th Street Iowa City IA 52242 426004813 501c(3) 400468 DRUG DISCOVERY AWARDS The University of Iowa Office of Vice President for Resear Division of Sponsored Programs Iowa City IA 52242 426004813 501c(3) 172800 CLINICAL RESEARCH STUDY The University of North Carolina at Chapel Hill 300 Bynum Hall Division of Sponsored Programs Chapel Hill NC 275994100 566001393 501c(3) 1064941 DRUG DISCOVERY AWARDS The University of North Carolina at Chapel Hill 300 Bynum Hall CB 4100 Chapel Hill NC 275994100 566001393 501c(3) 797722 PHASE III TRIALS The University of North Carolina at Chapel Hill 300 Bynum Hall CB 4100 Chapel Hill NC 275994100 566001393 501c(3) 294955 CLINICAL RESEARCH STUDY The University of North Carolina at Chapel Hill 300 Bynum Hall CB 4100 Chapel Hill NC 275994100 566001393 501c(3) 204637 CLINICAL RESEARCH AWARDS The University of Utah 201 S Presidents Circle CB 4100 Salt Lake City UT 84112 876000525 501c(3) 100436 CLINICAL RESEARCH STUDY The University of Vermont and State Agricultural C Grant and Contract Administrative S Room 406 Burlington VT 05405 030179440 501c(3) 80438 CLINICAL RESEARCH STUDY Trustee of Indiana University Financial Management Services 223 Waterman Bldg Indianapolis IN 462666057 356001673 501c(3) 100548 CLINICAL RESEARCH STUDY Trustees of Dartmouth College Dartmouth Medical School PO Box 66057 Hanover NH 037551404 020222111 501c(3) 95211 ACADEMIC ADVISORY AWARDS University at Buffalo Pediatric Associates 239 Bryant Street Dept of Microbiology and Immunolog Buffalo NY 14222 161238821 501c(3) 128900 ACADEMIC ADVISORY AWARDS University at Buffalo Pediatric Associates 239 Bryant Street 2nd Floor Buffalo NY 14222 161238821 501c(3) 84672 CLINICAL RESEARCH STUDY University of Arkansas for Medical Sciences 4301 West Markham Street 2nd Floor Little Rock AR 72205 716046242 501c(3) 80438 CLINICAL RESEARCH STUDY University of Connecticut Office of Sponsored Programs Mail Slot 555 Storrs CT 062691133 060772160 501c(3) 98600 DRUG DISCOVERY AWARDS University of Kentucky Research Foundation 337 Peterson 438 Whitney Road Ext U-1133 Lexington KY 405060005 616033693 501c(3) 76416 CLINICAL RESEARCH STUDY University of Massachusetts Medical School 55 Lake Avenue North Worcester MA 01655 043167352 501c(3) 57312 CLINICAL RESEARCH STUDY University of Miami PO Box 025405 Miami FL 331025405 590624458 501c(3) 74088 CLINICAL RESEARCH STUDY University of Nebraska Medical Center 985100 Nebraska Medical Center Omaha NE 681985190 470491233 501c(3) 80438 CLINICAL RESEARCH STUDY University of Oklahoma Health Sciences Center PO Box 26901 Oklahoma City OK 73190 736017987 501c(3) 74088 CLINICAL RESEARCH STUDY University of Pittsburgh 350 Thackeray Hall Pittsburgh PA 15260 250965591 501c(3) 422250 DRUG DISCOVERY AWARDS University of Pittsburgh 350 Thackeray Hall Pittsburgh PA 15260 250965591 501c(3) 204598 CLINICAL RESEARCH STUDY University of Rochester Box 649 Rochester NY 14642 160743209 501c(3) 76416 CLINICAL RESEARCH STUDY University of South Alabama Admin Bldg 362 601 Elmwood Avenue Mobile AL 36688 630477348 501c(3) 88932 DRUG DISCOVERY AWARDS University of Tennessee 62 S Dunlap Memphis TN 38163 626001636 501c(3) 83589 CLINICAL RESEARCH STUDY University of Texas Health Science Center at San A Office of Sponsored Programs MC 78 San Antonio TX 78229 741586031 501c(3) 74088 CLINICAL RESEARCH STUDY University of Washington Office of Sponsored Programs 7703 Floyd Curl Drive Seattle WA 981056692 916001537 501c(3) 56961 DRUG DISCOVERY AWARDS University of Washington Office of Sponsored Programs 4333 Brooklyn Avenue NE Seattle WA 981056692 916001537 501c(3) 32248 CLINICAL RESEARCH AWARDS University of Washington Grant Contract Accounting 4333 Brooklyn Avenue NE Seattle WA 981056692 916001537 501c(3) 10996 ACADEMIC ADVISORY AWARDS University of Wisconsin Board of Regents 750 University Avenue 3917 University Way NE Madison WI 53706 396006492 501c(3) 84041 CLINICAL RESEARCH AWARDS University of Wisconsin Board of Regents 750 University Avenue Madison WI 53706 396006492 501c(3) 70384 CLINICAL RESEARCH STUDY UT Southwestern Medical Center at Dallas 5323 Harry Hines Boulevard Dallas TX 753909105 756002868 501c(3) 295939 DRUG DISCOVERY AWARDS UT Southwestern Medical Center at Dallas 5323 Harry Hines Boulevard Dallas TX 753909105 756002868 501c(3) 80438 CLINICAL RESEARCH STUDY Vanderbilt University Medical Center PO Box 30195 Nashville TN 372410195 620476822 501c(3) 76416 CLINICAL RESEARCH STUDY Via Christi Regional Medical Center Inc 707 N Emporia Wichita KS 67214 481172106 501c(3) 60329 CLINICAL RESEARCH STUDY Virginia Commonwealth University Box 2506 - VCU Station Richmond VA 232842506 546001758 501c(3) 80438 CLINICAL RESEARCH STUDY Washington University 660 S Euclid Avenue St Louis MO 63110 430653611 501c(3) 80435 CLINICAL RESEARCH STUDY Wayne State University Grants Contracts Office III Detroit MI 48201 383028425 501c(3) 78830 CLINICAL RESEARCH STUDY West Virginia University Research Corporation WVU Research and Sponsored Programs Morgantown WV 265066001 550665758 501c(3) 66864 CLINICAL RESEARCH STUDY Yale University 47 College Street Suite 203 One Waterfront Place New Haven CT 065208047 060646973 501c(3) 57312 CLINICAL RESEARCH STUDY 86 PROCEDURES FOR MONITORING GRANT FUNDS INSIDE OF THE U.S. PART I, LINE 2 THE ORGANIZATION HAS PROCEDURES IN PLACE TO MONITOR THE SCIENTIFIC PROGRESS AND FINANCIAL ASPECTS OF GRANT FUNDS AWARDED TO ENTITIES INSIDE OF THE US. SPONSORED INSTITUTIONS ARE REQUIRED TO SUBMIT ANNUAL REPORTS OF EXPENDITURES AS WELL AS SCIENTIFIC PROGRESS REPORTS. SCIENTIFIC REPORTS ARE REVIEWED BY THE ORGANIZATION'S SCIENTIFIC STAFF TO ENSURE ACCEPTABLE PROGRESS HAS BEEN ATTAINED. THE FINAL GRANT PAYMENT IS CONTINGENT UPON RECEIPT AND APPROVAL OF THE REPORT OF EXPENDITURES. REPORTS OF EXPENDITURES ARE REVIEWED AND APPROVED BY STAFF TO ENSURE INCURRED COSTS ARE APPROPRIATE. THE CF FOUNDATION'S INTERNAL AUDITORS CONDUCT AUDITS ON SAMPLES OF GRANT EXPENDITURE REPORTS BY EXAMINING SUPPORTING RECORDS FROM THE SPONSORED INSTITUTIONS. X X X X X X false true false false false false false false false Robert J Beall PhD 168556 333873 57997 117753 7935 25439 104851 238007 0 19314 339339 734386 Preston W Campbell MD 118606 229481 32309 65596 5445 15701 71573 170443 0 26877 227933 508098 C Richard Mattingly 0 358018 0 95553 0 21749 0 267345 0 17114 0 759779 Vera H Twigg 0 244233 0 62993 0 18002 0 93694 0 26261 0 445183 BRUCE MARSHALL MD 288271 0 48860 0 2322 0 25128 0 901 0 365482 0 MARTIN MENSE 142786 0 18200 0 289 0 16353 0 27461 0 205089 0 SUPPLEMENTAL NONQUALIFIED RETIREMENT PLAN PART I, LINE 4B PART I, LINE 4B: CERTAIN PERSONS LISTED IN FORM 990, PART VII, SECTION A PARTICIPATE IN A NONQUALIFIED DEFERRED COMPENSATION PLAN, UNDER WHICH INTERESTS ARE FORFEITED BY THE PARTICIPANT IF THE PARTICIPANT VOLUNTARILY TERMINATES EMPLOYMENT PRIOR TO DESIGNATED VESTING DATE. FURTHER INFORMATION ABOUT THE NONQUALIFIED DEFERRED COMPENSATION PLAN IN WHICH THOSE PERSONS PARTICIPATE IS PROVIDED IN THE ADDITIONAL INFORMATION FOR SCHEDULE J, PART II, BELOW. COMPENSATION PART II CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (A) NAME: R. BEALL, PH.D.; (B)(I) BASE COMPENSATION: BASE SALARY - $161,296, 401(K) BONUS - $7,260; (B)(II) BONUS & INCENTIVE COMPENSATION: ANNUAL INCENTIVE PLAN BENEFIT (1) - $57,997; (B)(III) OTHER REPORTABLE COMPENSATION: HEALTH INSURANCE BENEFIT - $1,434, AUTOMOBILE ALLOWANCE - $2,376, OTHER BENEFITS INCLUDING GENERAL ORGANIZATION GROUP TERM LIFE INSURANCE PREMIUM - $4,125; (C) DEFERRED COMPENSATION: LONG-TERM INCENTIVE PLAN BENEFIT (6) - $72,511, SERP (3) - $32,340; (D) NONTAXABLE BENEFITS: $0 CYSTIC FIBROSIS FOUNDATION - HEADQUARTERS. EIN 13-1930701. (A) NAME: R. BEALL, PH.D.; (B)(I) BASE COMPENSATION: BASE SALARY - $319,133, 401(K) BONUS - $14,740; (B)(II) BONUS & INCENTIVE COMPENSATION: ANNUAL INCENTIVE PLAN BENEFIT (1) - $117,753; (B)(III) OTHER REPORTABLE COMPENSATION: HEALTH INSURANCE BENEFIT - $2,912, AUTOMOBILE ALLOWANCE - $4,824, OTHER BENEFITS INCLUDING TAXABLE GENERAL ORGANIZATION GROUP TERM LIFE INSURANCE PREMIUM - $17,703; (C) DEFERRED COMPENSATION: RETIREMENT BENEFIT (2) - $25,128, LONG-TERM INCENTIVE PLAN BENEFIT (6) - $147,219, SERP (3) - $65,660; (D) NONTAXABLE BENEFITS: EMPLOYER CONTRIBUTION TO GENERAL ORGANIZATION HEALTH PLAN BENEFIT - $10,968, EMPLOYEE CONTRIBUTION TO FLEXIBLE SPENDING ACCOUNT BENEFIT - $4,000, EMPLOYEE CONTRIBUTION TO GENERAL ORGANIZATION HEALTH PLAN BENEFIT - $4,346 CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (A) NAME: P. CAMPBELL, M.D.; (B)(I) BASE COMPENSATION: BASE SALARY - $118,606; (B)(II) BONUS & INCENTIVE COMPENSATION: ANNUAL INCENTIVE PLAN BENEFIT (1) - $32,309; (B)(III) OTHER REPORTABLE COMPENSATION: SECTION 457(B) PLAN (5) - $5,445; (C) DEFERRED COMPENSATION: LONG-TERM INCENTIVE PLAN BENEFIT (6) - $53,378, SERP (4) - $18,195; (D) NONTAXABLE BENEFITS: $0 CYSTIC FIBROSIS FOUNDATION - HEADQUARTERS. EIN 13-1930701. (A) NAME: P. CAMPBELL, M.D.; (B)(I) BASE COMPENSATION: BASE SALARY - $229,481; (B)(II) BONUS & INCENTIVE COMPENSATION: ANNUAL INCENTIVE PLAN BENEFIT (1) - $65,596; (B)(III) OTHER REPORTABLE COMPENSATION: OTHER BENEFITS INCLUDING TAXABLE GENERAL ORGANIZATION GROUP TERM LIFE INSURANCE PREMIUM - $4,646, SECTION 457(B) PLAN (5) - $11,055; (C) DEFERRED COMPENSATION: RETIREMENT BENEFIT (2) - $25,128, LONG-TERM INCENTIVE PLAN BENEFIT (6) - $108,374, SERP (4) - $36,941; (D) NONTAXABLE BENEFITS: EMPLOYER CONTRIBUTION TO GENERAL ORGANIZATION HEALTH PLAN BENEFIT - $15,552, EMPLOYEE CONTRIBUTION TO FLEXIBLE SPENDING ACCOUNT BENEFIT - $5,000, EMPLOYEE CONTRIBUTION TO GENERAL ORGANIZATION HEALTH PLAN BENEFIT - $6,325 CYSTIC FIBROSIS FOUNDATION - HEADQUARTERS. EIN 13-1930701. NAME: (A) R. MATTINGLY; (B)(I) BASE COMPENSATION: BASE SALARY - $358,018; (B)(II) BONUS & INCENTIVE COMPENSATION: ANNUAL INCENTIVE PLAN BENEFIT (1) - $95,553; (B)(III) OTHER REPORTABLE COMPENSATION: SECTION 457(B) PLAN (5) - $16,500; OTHER BENEFITS INCLUDING TAXABLE GENERAL ORGANIZATION GROUP TERM LIFE INSURANCE PREMIUM - $5,249; (C) DEFERRED COMPENSATION: RETIREMENT BENEFIT (2) - $25,128, LONG-TERM INCENTIVE PLAN BENEFIT (6) - $163,713, SERP (4) - $78,504; (D) NONTAXABLE BENEFITS: EMPLOYER CONTRIBUTION TO GENERAL ORGANIZATION HEALTH PLAN BENEFIT - $10,968, EMPLOYEE CONTRIBUTION TO FLEXIBLE SPENDING ACCOUNT BENEFIT - $1,800, EMPLOYEE CONTRIBUTION TO GENERAL ORGANIZATION HEALTH PLAN BENEFIT - $4,346 CYSTIC FIBROSIS FOUNDATION - HEADQUARTERS. EIN 13-1930701. (A) NAME: V. TWIGG; (B)(I) BASE COMPENSATION: BASE SALARY - $244,233; (B)(II) BONUS & INCENTIVE COMPENSATION: ANNUAL INCENTIVE PLAN BENEFIT (1) - $62,993; (B)(III) OTHER REPORTABLE COMPENSATION: TAXABLE GENERAL ORGANIZATION GROUP TERM LIFE INSURANCE PREMIUM - $1,611, SECTION 457(B) PLAN (5) - $16,391; (C) DEFERRED COMPENSATION: RETIREMENT BENEFIT (2) - $25,128, LONG-TERM INCENTIVE PLAN BENEFIT (6) - $68,566; (D) NONTAXABLE BENEFITS: EMPLOYER CONTRIBUTION TO GENERAL ORGANIZATION HEALTH PLAN BENEFIT - $16,571, EMPLOYEE CONTRIBUTION TO FLEXIBLE SPENDING ACCOUNT BENEFIT - $5,000, EMPLOYEE CONTRIBUTION TO GENERAL ORGANIZATION HEALTH PLAN BENEFIT - $4,690 (1) THIS IS AN AWARD BASED ON ACHIEVEMENT OF ANNUAL PERFORMANCE STANDARDS ESTABLISHED IN ADVANCE BY THE COMPENSATION COMMITTEE OF THE CFF BOARD. (2) THIS IS THE EMPLOYER CONTRIBUTION MADE UNDER THE CYSTIC FIBROSIS FOUNDATION 401(K) PLAN FOR THE 2011 PLAN YEAR. (3) THE SERP IS SPONSORED BY CFF, A RELATED ORGANIZATION. THE EXECUTIVE PARTICIPATES BY VIRTUE OF BEING AN OFFICER OF CFF. CFFT MAKES CONTRIBUTIONS ON THE PARTICIPANT'S BEHALF TO THE SERP. A. THIS IS AN UNVESTED EMPLOYER CONTRIBUTION TO THE SERP. B. SERP INTERESTS ARE FORFEITED BY THE PARTICIPANT IF THE PARTICIPANT VOLUNTARILY TERMINATES EMPLOYMENT PRIOR TO DECEMBER 31, 2012. C. SERP INTERESTS ARE HELD IN A TRUST SUBJECT TO THE CLAIMS OF CFF'S BANKRUPTCY CREDITORS. IN THE EVENT OF A CFF BANKRUPTCY, PARTICIPANTS WOULD BECOME GENERAL UNSECURED CREDITORS OF CFF. D. THE SERP IS A NONQUALIFIED DEFERRED COMPENSATION PLAN. THIS MEANS THAT PARTICIPANTS DO NOT RECEIVE THE TAX BENEFITS AVAILABLE TO PARTICIPANTS IN TAX QUALIFIED RETIREMENT PLANS. FOR EXAMPLE, UNDER CURRENT LAW, INTERESTS UNDER SERPS ARE REPORTABLE AS TAXABLE COMPENSATION WHEN THEY BECOME VESTED, EVEN IF THOSE AMOUNTS ARE NOT YET PAYABLE TO THE PARTICIPANT (AND EVEN IF THOSE AMOUNTS ARE NEVER PAID TO THE PARTICIPANT). E. THE SERP'S DESIGN WAS REVIEWED AND OPINED UPON AS REASONABLE BY AN INDEPENDENT COMPENSATION CONSULTANT. SERP CONTRIBUTION AMOUNTS WERE DETERMINED BY AN INDEPENDENT ACTUARY. F. CFF RETAINS THE RIGHT TO AMEND OR TERMINATE THE SERP AT ANY TIME. (4) THE SERP IS SPONSORED BY CFF, A RELATED ORGANIZATION. THE EXECUTIVE PARTICIPATES BY VIRTUE OF BEING AN OFFICER OF CFF. CFFT MAKES CONTRIBUTIONS ON THE PARTICIPANT'S BEHALF TO THE SERP. A. THIS IS AN UNVESTED EMPLOYER CONTRIBUTION TO THE SERP. B. SERP INTERESTS ARE FORFEITED BY THE PARTICIPANT IF THE PARTICIPANT VOLUNTARILY TERMINATES EMPLOYMENT PRIOR TO ATTAINING AGE 60. C. IN THE EVENT OF A CFF BANKRUPTCY, PARTICIPANTS ARE GENERAL UNSECURED CREDITORS OF CFF. D. THE SERP IS A NONQUALIFIED DEFERRED COMPENSATION PLAN. THIS MEANS THAT PARTICIPANTS DO NOT RECEIVE THE TAX BENEFITS AVAILABLE TO PARTICIPANTS IN TAX QUALIFIED RETIREMENT PLANS. FOR EXAMPLE, UNDER CURRENT LAW, INTERESTS UNDER SERPS ARE REPORTABLE AS TAXABLE COMPENSATION WHEN THEY BECOME VESTED, EVEN IF THOSE AMOUNTS ARE NOT YET PAYABLE TO THE PARTICIPANT (AND EVEN IF THOSE AMOUNTS ARE NEVER PAID TO THE PARTICIPANT). E. THE SERP'S DESIGN WAS REVIEWED AND OPINED UPON AS REASONABLE BY AN INDEPENDENT COMPENSATION CONSULTANT. AN INDEPENDENT ACTUARY DEVELOPED THE CONTRIBUTION FORMULA PURSUANT TO WHICH SERP CONTRIBUTION AMOUNTS ARE DETERMINED. F. CFF RETAINS THE RIGHT TO AMEND OR TERMINATE THE SERP AT ANY TIME. (5) THE 457(B) PLAN IS SPONSORED BY CFF, A RELATED ORGANIZATION. THE EXECUTIVE PARTICIPATES BY VIRTUE OF BEING AN OFFICER OF CFF. CFFT MAKES CONTRIBUTIONS ON THE PARTICIPANT'S BEHALF TO THE PLAN. A. THIS IS A VESTED CONTRIBUTION TO THE 457(B) PLAN FOR THE REPORTING PERIOD. B. IN THE EVENT OF A CFF BANKRUPTCY, PARTICIPANTS ARE GENERAL UNSECURED CREDITORS OF CFF. C. DISTRIBUTIONS FROM THE 457(B) PLAN MAY NOT BE ROLLED-OVER TO AN IRA OR QUALIFIED PLAN (BUT MAY ONLY BE ROLLED-OVER TO ANOTHER 457(B) PLAN). D. THE 457(B) PLAN'S DESIGN WAS REVIEWED AND OPINED UPON AS REASONABLE BY AN INDEPENDENT COMPENSATION CONSULTANT. AN INDEPENDENT ACTUARY DEVELOPED THE CONTRIBUTION FORMULA PURSUANT TO WHICH 457(B) CONTRIBUTION AMOUNTS ARE DETERMINED. CONTRIBUTIONS TO THE 457(B) PLAN ARE SUBJECT TO ANNUAL IRS LIMITS (CURRENTLY $16,500). E. CFF RETAINS THE RIGHT TO AMEND OR TERMINATE THE 457(B) PLAN AT ANY TIME. (6) THIS PLAN PROVIDES FOR AWARDS THAT RELATE TO A THREE-YEAR PERFORMANCE PERIOD, BASED ON ACHIEVEMENT OF PERFORMANCE OBJECTIVES ESTABLISHED IN ADVANCE BY THE COMPENSATION COMMITTEE OF THE BOARD. EACH YEAR, A NEW THREE YEAR PERFORMANCE PERIOD BEGINS. AS REQUIRED BY THE FORM 990 INSTRUCTIONS, THE AMOUNTS REPORTED ON THIS FORM 990 REFLECT AN ESTIMATE OF THE PORTION OF EACH AWARD THAT THE EXECUTIVE ACCRUED UNDER THE PLAN FOR PERFORMANCE IN 2011 (I.E., WITH RESPECT TO THE 2010-2012 AND THE 2011-2013 PERFORMANCE PERIODS), BUT THE AMOUNTS REPORTED HAVE NOT BEEN EARNED, AWARDED OR PAID UNDER THE PLAN. THE INDIVIDUAL MUST BE EMPLOYED ON 12/31/12 AND 12/31/13 TO BE ELIGIBLE TO RECEIVE FULL PAYMENT OF THE AWARD FOR THE 2010-2012 AND THE 2011-2013 PERFORMANCE PERIODS, RESPECTIVELY. GOVERNING BODY APPOINTMENTS Part VI, Section A, Line 7a (Page 6 Core Form) CERTAIN OF THE ORGANIZATION'S BOARD MEMBERS ARE DESIGNATED BY THE BOARD OF TRUSTEES OF THE CYSTIC FIBROSIS FOUNDATION. REVIEW OF 990 BY GOVERNING BODY Part VI, Section B, Line 11b (Page 6 Core Form) THE ORGANIZATION'S BOARD OF DIRECTORS RECEIVES A DRAFT OF THE FORM 990 PRIOR TO ITS BEING FILED, WITH SUFFICIENT TIME FOR REVIEW AND COMMENT ALLOWED. THE ORGANIZATION'S ERISA ATTORNEYS REVIEW THE EXECUTIVE COMPENSATION SECTIONS OF THE FORM 990 TO ENSURE COMPLETENESS AND ACCURACY. THE AUDIT COMMITTEE ALSO REVIEWS THE FORM 990 AS PART OF ITS CHARTERED RESPONSIBILITIES. CONFLICT OF INTEREST MONITORING Part VI, Section B, Line 12c (Page 6 Core Form) A CONFLICT OF INTEREST DISCLOSURE STATEMENT IS COMPLETED ANNUALLY BY EACH BOARD MEMBER AND OFFICER. DISCLOSURES PROVIDED ARE REPORTED TO THE NOMINATING AND GOVERNANCE COMMITTEE, THE AUDIT COMMITTEE AND THE BOARD OF TRUSTEES. AS REQUIRED WITHIN THE BYLAWS, ANY POTENTIAL CONFLICTS OF INTEREST MUST BE REPORTED TO THE BOARD AS THEY ARISE. WHEN ANY MATTER IS DEEMED A POTENTIAL CONFLICT OF INTEREST AND REQUIRES ACTION BY THE BOARD OF TRUSTEES, THE INTERESTED TRUSTEE OR OFFICER IS REQUIRED TO RETIRE FROM THE ROOM IN WHICH THE BOARD OR ITS COMMITTEE IS MEETING, MAY NOT PARTICIPATE IN THE FINAL DELIBERATION OF THE MATTER, AND MAY NOT VOTE ON THE MATTER. THE ORGANIZATION ENFORCED THE POLICY DURING 2011 AND HAD NO CONFLICTS OF INTEREST AS DEFINED BY THE POLICY. DETERMINING COMPENSATION Part VI, Section B, Line 15a and 15b (Page 6 Core Form) THE TOTAL COMPENSATION OF EXECUTIVES AT THE CYSTIC FIBROSIS FOUNDATION IS SPECIFICALLY DESIGNED TO ATTRACT AND RETAIN THE HIGHEST QUALIFIED EXECUTIVE AND MEDICAL TALENT TO FULFILL THE CRITICALLY IMPORTANT MISSION OF ASSURING THE DEVELOPMENT OF THE MEANS TO CURE AND CONTROL CF AND IMPROVING THE QUALITY OF LIFE FOR THOSE WITH THE DISEASE. THE INDEPENDENT COMPENSATION COMMITTEE OF THE CF FOUNDATION'S BOARD OF TRUSTEES FOLLOWS THE PROCESS DESCRIBED IN THE IRS INTERMEDIATE SANCTIONS RULES WHEN DETERMINING COMPENSATION. SPECIFICALLY, THE COMMITTEE: 1. IS COMPOSED ENTIRELY OF NON-EMPLOYEE VOLUNTEER DIRECTORS WHO HAVE NO FAMILIAL, BUSINESS OR SIGNIFICANT PERSONAL RELATIONSHIPS WITH THE CF FOUNDATION OR ITS EXECUTIVES. 2. ASSESSES THE SHORT-TERM AND LONG-TERM CONTRIBUTION AND PERFORMANCE OF EACH EXECUTIVE IN MEETING VERY DEFINITIVE AND QUANTIFIABLE OBJECTIVES FOCUSED ON THE CF FOUNDATION'S MISSION SUCCESS. 3. ENGAGES AN INDEPENDENT COMPENSATION CONSULTING FIRM TO COMPILE APPROPRIATE COMPARABILITY DATA (INCLUDING COMPENSATION MARKET INFORMATION FOR PEERS WITH WHOM THE CF FOUNDATION COMPETES FOR EXECUTIVE TALENT) FOR COMMITTEE RELIANCE. THE COMMITTEE MEETS WITH REPRESENTATIVES OF THE CONSULTING FIRM TO REVIEW THIS DATA IN DETAIL. 4. REVIEWS ALL ELEMENTS OF EACH EXECUTIVE'S TOTAL COMPENSATION, INCLUDING BUT NOT LIMITED TO BASE SALARY, BONUSES, PERQUISITES, FRINGE BENEFITS, AND INCENTIVE AND DEFERRED COMPENSATION ARRANGEMENTS. UPON THE EXECUTIVE'S HIRE, AND AT EACH POINT IN TIME THEREAFTER AT WHICH A NEW OR REVISED COMPENSATION ARRANGEMENT IS UNDER CONSIDERATION WITH RESPECT TO THE EXECUTIVE, THE COMMITTEE MEETS WITH ITS INDEPENDENT COMPENSATION CONSULTING FIRM BEFORE THE ARRANGEMENT IS IMPLEMENTED TO EVALUATE THE REASONABLENESS OF THE ARRANGEMENT BY COMPARING BOTH THE ARRANGEMENT ITSELF AND THE EXECUTIVE'S ENTIRE COMPENSATION PACKAGES TO COMPENSATION PACKAGES PAID BY SIMILARLY SITUATED ORGANIZATIONS FOR FUNCTIONALLY COMPARABLE POSITIONS. 5. DOCUMENTS, CONCURRENTLY WITH ITS DETERMINATION, THE BASIS FOR ITS DETERMINATION IN THE MINUTES OF ITS MEETING. THESE MINUTES ARE REVIEWED, REVISED IF NECESSARY AND APPROVED AT THE FOLLOWING MEETING OF THE COMMITTEE. 6. OBTAINS A WRITTEN LEGAL OPINION CONCERNING THE COMMITTEE'S COMPLIANCE WITH THE IRS INTERMEDIATE SANCTIONS RULES. THE PROCESS DESCRIBED ABOVE WAS LAST USED IN 2009 TO ESTABLISH COMPENSATION FOR THE FOLLOWING OFFICERS OR POSITIONS: PRESIDENT & CEO EXECUTIVE VICE PRESIDENT & COO EXECUTIVE VICE PRESIDENT FOR MEDICAL AFFAIRS SENIOR VICE PRESIDENT & CFO IN ADDITION, IN DECEMBER 2010, THE COMPENSATION COMMITTEE REVIEWED THE EXECUTIVES' PERFORMANCE, RECENT INDEPENDENTLY PREPARED COMPENSATION DATA, AND OTHER CHANGES RELEVANT TO THE ENVIRONMENT OF THE CF FOUNDATION TO APPROVE INCREASES IN THE EXECUTIVES' SALARY FOR CALENDAR YEAR 2011. THE COMPENSATION COMMITTEE DOCUMENTED THE BASIS FOR ITS DETERMINATION IN THE MINUTES OF ITS MEETING. THESE MINUTES WERE REVIEWED AND APPROVED AT THE FOLLOWING MEETING OF THE COMPENSATION COMMITTEE. PUBLIC INSPECTION Part VI, Section C, Line 19 (Page 6 Core Form) THE FORM 1023 FOR THE ORGANIZATION WAS AVAILABLE ON ITS WEBSITE, CFF.ORG AND THE ORGANIZATION'S WEBSITE PROVIDES A LINK TO GUIDESTAR.ORG FOR ACCESS TO FORM 990. CFFT'S GOVERNING DOCUMENTS (BYLAWS AND ARTICLES OF INCORPORATION) ARE AVAILABLE UPON REQUEST BY CONTACTING THE NATIONAL OFFICE OF THE CYSTIC FIBROSIS FOUNDATION IN WRITING OR BY PHONE. INFORMATION ON HOW TO OBTAIN THE GOVERNING DOCUMENTS IS AVAILABLE ON THE WEBSITE, WWW.CFF.ORG/RESEARCH/CFFT. THE BOARD AND OFFICER CONFLICT OF INTEREST POLICY AND THE AUDITED FINANCIAL STATEMENTS ARE AVAILABLE ON THE WEBSITE, WWW.CFF.ORG/RESEARCH/CFFT. COMPENSATION OF OFFICERS, DIRECTORS, TRUSTEES, ETC FORM 990, PART VII, SECTION A NAME AND TITLE THEODORE J. TORPHY,PH.D, CHAIRMAN AVG HRS WORKED 5 HRS POSITION DIRECTOR REPORTABLE COMP FROM THE ORG NONE REPORTABLE COMP FROM RELATED ORG NONE EST. AMT OF OTHER COMP FROM THE ORG NONE NAME AND TITLE STEVEN SHAK, MD., DIRECTOR AVG HRS WORKED 3 HRS POSITION DIRECTOR REPORTABLE COMP FROM THE ORG NONE REPORTABLE COMP FROM RELATED ORG NONE EST. AMT OF OTHER COMP FROM THE ORG NONE NAME AND TITLE CATHERINE C. MCLOUD, DIRECTOR AVG HRS WORKED 3 HRS POSITION DIRECTOR REPORTABLE COMP FROM THE ORG NONE REPORTABLE COMP FROM RELATED ORG NONE EST. AMT OF OTHER COMP FROM THE ORG NONE NAME AND TITLE JONATHAN COHN, MD, DIRECTOR AVG HRS WORKED 3 HRS POSITION DIRECTOR REPORTABLE COMP FROM THE ORG NONE REPORTABLE COMP FROM RELATED ORG NONE EST. AMT OF OTHER COMP FROM THE ORG NONE NAME AND TITLE JASON M. ARYEH, DIRECTOR AVG HRS WORKED 3 HRS POSITION DIRECTOR REPORTABLE COMP FROM THE ORG NONE REPORTABLE COMP FROM RELATED ORG NONE EST. AMT OF OTHER COMP FROM THE ORG NONE NAME AND TITLE D. PAUL FLESSNER, DIRECTOR AVG HRS WORKED 3 HRS POSITION DIRECTOR REPORTABLE COMP FROM THE ORG NONE REPORTABLE COMP FROM RELATED ORG NONE EST. AMT OF OTHER COMP FROM THE ORG NONE NAME AND TITLE ROBERT J. BEALL, PH.D, PRES/CEO AVG HRS WORKED 18 HRS POSITION DIRECTOR & OFFICER REPORTABLE COMP FROM THE ORG 234,488 REPORTABLE COMP FROM RELATED ORG 477,065 EST. AMT OF OTHER COMP FROM THE ORG 362,172 NAME AND TITLE PRESTON W. CAMPBELL, M.D., EXEC VP OF MEDICAL AFFAIRS AVG HRS WORKED 18 HRS POSITION OFFICER REPORTABLE COMP FROM THE ORG 156,360 REPORTABLE COMP FROM RELATED ORG 310,778 EST. AMT OF OTHER COMP FROM THE ORG 268,893 NAME AND TITLE C. RICHARD MATTINGLY, EXEC VP/COO AVG HRS WORKED 5 HRS POSITION OFFICER REPORTABLE COMP FROM THE ORG NONE REPORTABLE COMP FROM RELATED ORG 475,320 EST. AMT OF OTHER COMP FROM THE ORG 284,459 NAME AND TITLE VERA H. TWIGG, SR VP & CFO AVG HRS WORKED 5 HRS POSITION OFFICER REPORTABLE COMP FROM THE ORG NONE REPORTABLE COMP FROM RELATED ORG 325,228 EST. AMT OF OTHER COMP FROM THE ORG 119,955 NAME AND TITLE BRUCE MARSHALL, MD, VP OF CLINICAL AFFAIRS AVG HRS WORKED 50 HRS POSITION KEY EMPLOYEE REPORTABLE COMP FROM THE ORG 339,453 REPORTABLE COMP FROM RELATED ORG NONE EST. AMT OF OTHER COMP FROM THE ORG 26,029 NAME AND TITLE CYNTHIA GEORGE, MDS, FNP, BC DIRECTOR OF CLINICAL RESOURCES AVG HRS WORKED 50 HRS POSITION HIGHEST COMPENSATED EMPLOYEE REPORTABLE COMP FROM THE ORG 111,524 REPORTABLE COMP FROM RELATED ORG NONE EST. AMT OF OTHER COMP FROM THE ORG 15,333 NAME AND TITLE MARTIN MENSE, PH.D, PRINCIPAL SCIENTIST FOR DRUG DISCOVERY AVG HRS WORKED 50 HRS POSITION HIGHEST COMPENSATED EMPLOYEE REPORTABLE COMP FROM THE ORG 161,275 REPORTABLE COMP FROM RELATED ORG NONE EST. AMT OF OTHER COMP FROM THE ORG 43,814 NAME AND TITLE ELIZABETH JOSELOFF, PH.D. INTEGRATIVE BIOLOGY DIRECTOR AVG HRS WORKED 50 HRS POSITION HIGHEST COMPENSATED EMPLOYEE REPORTABLE COMP FROM THE ORG 103,125 REPORTABLE COMP FROM RELATED ORG NONE EST. AMT OF OTHER COMP FROM THE ORG 27,904 TOTAL REPORTABLE COMP FROM THE ORG 1,106,225 TOTAL REPORTABLE COMP FROM RELATED ORG 1,588,391 TOTAL EST. AMT OF OTHER COMP FROM THE ORG 1,148,559 HOURS DEVOTED FOR RELATED ORGANIZATION FORM 990 PART VII NAME:Robert J. Beall, Ph.D. TITLE:President & CEO HOURS:39 HOURS DEVOTED FOR RELATED ORGANIZATION FORM 990 PART VII NAME:Preston W. Campbell, MD TITLE:Exec VP of Medical Affairs HOURS:39 HOURS DEVOTED FOR RELATED ORGANIZATION FORM 990 PART VII NAME:C. Richard Mattingly TITLE:Exec VP and COO HOURS:55 HOURS DEVOTED FOR RELATED ORGANIZATION FORM 990 PART VII NAME:Vera H. Twigg TITLE:Sr. VP and CFO HOURS:55 CYSTIC FIBROSIS FOUNDATION-HEADQUARTERS 6931 ARLINGTON RD bethesda MD 20814 131930701 research DE 501(c)(3) 7 na false CYSTIC FIBROSIS FOUNDATION - GROUP 6931 ARLINGTON RD BETHESDA MD 20814 136161105 EDUCATION DE 501(c)(3) 7 CFF-HQ false CYSTIC FIBROSIS SERVICES INC 6931 ARLINGTON RD BETHESDA MD 20814 521850490 pharmacy MD CFF PHARMACY c false false true false false false false false false false false false true true false false false false Cystic fibrosis foundation - headquarters 1c 49932523 FMV Cystic fibrosis foundation - headquarters 1M 255145 FMV Cystic fibrosis foundation - headquarters 1N 1640186 FMV